Selective Estrogen Receptor Modulators
"Selective Estrogen Receptor Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)
| Descriptor ID |
D020845
|
| MeSH Number(s) |
D06.347.360.827 D27.505.696.399.450.360.827
|
| Concept/Terms |
Selective Estrogen Receptor Modulators- Selective Estrogen Receptor Modulators
- SERMs
- Estrogen Receptor Modulators, Selective
- Selective Estrogen Receptor Modulator
- SERM
- Estrogen Receptor Modulator, Selective
|
Below are MeSH descriptors whose meaning is more general than "Selective Estrogen Receptor Modulators".
Below are MeSH descriptors whose meaning is more specific than "Selective Estrogen Receptor Modulators".
This graph shows the total number of publications written about "Selective Estrogen Receptor Modulators" by people in this website by year, and whether "Selective Estrogen Receptor Modulators" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Selective Estrogen Receptor Modulators" by people in Profiles.
-
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019 09 03; 322(9):868-886.
-
Bone loss in women with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2018 03; 148(3):535-539.
-
Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3).
-
Estrogen or raloxifene during postmenopausal weight loss: adiposity and cardiometabolic outcomes. Obesity (Silver Spring). 2014 Apr; 22(4):1024-31.
-
Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. Breast Cancer Res. 2013; 15(5):R74.
-
Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat. 2011 Jun; 127(3):681-8.
-
Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat. 2010 Feb; 119(3):613-20.
-
Testing whether decision aids introduce cognitive biases: results of a randomized trial. Patient Educ Couns. 2010 Aug; 80(2):158-63.
-
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008 Feb 01; 26(4):549-55.
-
Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008 Apr; 108(3):421-6.